BMY Furnishes earnings results (Ex. 99.1)
Summary
Bristol Myers Squibb reported strong second quarter 2026 financial results on July 30, 2026, via an earnings press release (Ex. 99.1). The company also raised its full-year 2026 outlook for both revenue and non-GAAP EPS. * Q2 revenues increased 6% to $13.0 billion. * Growth Portfolio revenues grew 15% to $7.6 billion. * GAAP EPS was $1.62, non-GAAP EPS was $2.04. * 2026 revenue guidance raised to ~$49.0 billion to $50.0 billion; non-GAAP EPS to $6.75 to $7.00.
Why It Matters
The company's strong Q2 performance, including 6% revenue growth and 15% growth in its Growth Portfolio (via Ex. 99.1), led to a raised full-year 2026 revenue and non-GAAP EPS outlook. This signals positive momentum and improved future expectations for investors.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how BMY traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View BMY Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“On July 30, 2026, Bristol-Myers Squibb Company (the "Company") issued a press release (the "Earnings Press Release") on its website at www.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000014272
- Filing Date
- Thursday, July 30, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive